Natalizumab-associated Progressive Multifocal Leukoencephalopathy in Patients with Multiple Sclerosis: A Mini Review

Area of Science:

• Neurology
• Immunology
• Virology

Background:

• Progressive multifocal leukoencephalopathy (PML) is a rare, fatal demyelinating disease of the central nervous system.
• It is caused by the John Cunningham virus (JCV) and leads to white matter inflammation.
• PML is associated with immunodeficiency and immunosuppressive therapies, including those for multiple sclerosis (MS).

Purpose of the Study:

• To discuss drug-induced PML in the context of multiple sclerosis treatment.
• To outline diagnostic strategies for PML in MS patients.
• To review management approaches for PML in patients on disease-modifying therapies.

Main Methods:

• Literature review of PML cases in MS patients.
• Analysis of diagnostic criteria and imaging findings for PML.
• Review of treatment and management strategies for immunosuppression-related PML.

Main Results:

• Natalizumab, a disease-modifying therapy for MS, is associated with an increased risk of PML.
• Early diagnosis of PML is crucial for patient outcomes.
• Management involves discontinuation of offending agents and, in some cases, immune reconstitution therapies.

Conclusions:

• Drug-induced PML is a significant concern in MS patients, particularly those on natalizumab.
• Prompt diagnosis and appropriate management are essential to improve outcomes.
• Risk stratification and patient monitoring are key to preventing and managing PML.